BioNTech reports third quarter 2025 revenues of €1.5 billion and net loss of €28.7 million
BioNTech SE reported revenues of €1.5 billion for the third quarter of 2025, up from €1.2 billion in the same period last year. For the nine months ended September 30, 2025, revenues reached €2.0 billion, compared to €1.6 billion for the prior year period. The increase was primarily attributed to revenues from the company's collaboration with Bristol Myers Squibb, partially offset by lower sales volumes of COVID-19 vaccines. The company reported a net loss of €28.7 million for the third quarter of 2025, with a basic and diluted loss per share of €0.12. R&D expenses for the quarter were €564.8 million, while year-to-date R&D expenses totaled €1.6 billion. BioNTech strengthened its financial position to €16.7 billion in cash, cash equivalents, and security investments, and received a $1.5 billion payment from its partnership with Bristol Myers Squibb. The company increased its full-year 2025 revenue guidance to €2.6-2.8 billion and lowered expense guidance ranges for R&D, SG&A, and capital expenditures. BioNTech does not expect to report a positive net income for the 2025 financial year.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNTech SE published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001136574-en) on November 03, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.